These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

55 related items for PubMed ID: 3245857

  • 1. Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacy.
    Hanefeld M, Lang PD, Fischer S, Leonhardt W, Bergmann S, Jaross W.
    Arzneimittelforschung; 1988 Dec; 38(12):1835-7. PubMed ID: 3245857
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemia.
    Fischer S, Hanefeld M, Lang PD, Fücker K, Bergmann S, Gehrisch S, Leonhardt W, Jaross W.
    Arzneimittelforschung; 1990 Apr; 40(4):469-72. PubMed ID: 2192717
    [Abstract] [Full Text] [Related]

  • 3. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983 Apr; 33(8):1185-90. PubMed ID: 6685498
    [Abstract] [Full Text] [Related]

  • 4. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
    Branchi A, Rovellini A, Fiorenza AM, Sommariva D.
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
    [Abstract] [Full Text] [Related]

  • 5. Effect of bezafibrate and colestyramine in patients with primary hypercholesterolemia.
    Steinhagen-Thiessen E, Müller S, Holler HD, Lang PD.
    Arzneimittelforschung; 1987 Jun; 37(6):726-8. PubMed ID: 3311054
    [Abstract] [Full Text] [Related]

  • 6. A cross-over controlled study on beclobrate versus bezafibrate in the treatment of type IIb hyperlipoproteinaemia.
    Avogaro P, Bittolo Bon G, Cazzolato G, Soldan S, Bufalino L.
    Drugs Exp Clin Res; 1989 Jun; 15(6-7):325-33. PubMed ID: 2686956
    [Abstract] [Full Text] [Related]

  • 7. [Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
    Lechleitner M, Sailer S, Irsigler H, Klein W, Patsch JR.
    Wien Med Wochenschr; 1995 Jun; 145(21):577-83. PubMed ID: 8560901
    [Abstract] [Full Text] [Related]

  • 8. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.
    Mathur S, Barradas MA, Mikhailidis DP, Dandona P.
    Diabetes Res; 1990 Jul; 14(3):133-8. PubMed ID: 2132185
    [Abstract] [Full Text] [Related]

  • 9. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.
    Waysbort J, Schwartz S, Brunner D.
    Arzneimittelforschung; 1994 Nov; 44(11):1217-22. PubMed ID: 7893284
    [Abstract] [Full Text] [Related]

  • 10. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J, Yamamoto K, Kobori S, Setoguchi Y, Sato Y, Matsunaga A, Shichiri M, Sakai T, Kono S, Arakawa K.
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [Abstract] [Full Text] [Related]

  • 11. [Statistical analysis of variations in total cholesterol, HDL, HDL2, HDL3, LDL-cholesterol, VLDL-triglycerides, apo-A and apo-B lipoproteins in dyslipidemias during antilipemic therapy].
    Melloni GF, Scarazatti E, Garanzelli P, Melloni R.
    Boll Soc Ital Biol Sper; 1985 Jan 30; 61(1):7-14. PubMed ID: 3884023
    [Abstract] [Full Text] [Related]

  • 12. Lovastatin versus bezafibrate: efficacy, tolerability, and effect on urinary mevalonate.
    Beil FU, Schrameyer-Wernecke A, Beisiegel U, Greten H, Karkas JD, Liou R, Alberts AW, Eckardt HG, Till AE.
    Cardiology; 1990 Jan 30; 77 Suppl 4():22-32. PubMed ID: 2073669
    [Abstract] [Full Text] [Related]

  • 13. Long lasting efficacy of Bezalip retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia.
    Császár A, Karádi I, Köszegi G, Pados G, Németh-Csóka M, Pichler M, Romics L.
    Klin Wochenschr; 1990 Jan 30; 68 Suppl 22():96-8. PubMed ID: 2087089
    [No Abstract] [Full Text] [Related]

  • 14. [Behavior of high-density lipoproteins in drug lipid-lowering treatment].
    Mordasini R, Riesen W, Oster P, Riva G.
    Schweiz Med Wochenschr; 1982 Jan 16; 112(3):95-8. PubMed ID: 7058319
    [Abstract] [Full Text] [Related]

  • 15. Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin.
    Lijnen P, Celis H, Desager JP, Fagard R.
    J Hum Hypertens; 1995 Jul 16; 9(7):557-64. PubMed ID: 7562885
    [Abstract] [Full Text] [Related]

  • 16. [Effects of simvastatin on plasma lipoproteins].
    Alessandri C, Basili S, Maurelli M, Andreozzi P, Bracaglia D, Cordova C.
    Clin Ter; 1994 Jan 16; 144(1):3-9. PubMed ID: 8168349
    [Abstract] [Full Text] [Related]

  • 17. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
    Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S.
    Circulation; 2004 May 11; 109(18):2197-202. PubMed ID: 15123532
    [Abstract] [Full Text] [Related]

  • 18. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
    Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A.
    Thromb Haemost; 1993 Aug 02; 70(2):241-3. PubMed ID: 8236126
    [Abstract] [Full Text] [Related]

  • 19. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia.
    Insull W, Davidson MH, Kulkarni PM, Siddhanti S, Ciaccia AV, Keech CA.
    Metabolism; 2005 Jul 02; 54(7):939-46. PubMed ID: 15988705
    [Abstract] [Full Text] [Related]

  • 20. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.
    J Am Coll Cardiol; 2008 Apr 22; 51(16):1564-72. PubMed ID: 18420099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.